| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Acumen Pharmaceuticals (NASDAQ:ABOS) is gearing up to announce its quarterly earnings on Thursday, 2025-03-27. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Acumen Pharmaceuticals will report an earnings per share (EPS) of $-0.40.
Anticipation surrounds Acumen Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
The company's EPS missed by $0.14 in the last quarter, leading to a 5.42% drop in the share price on the following day.
Here's a look at Acumen Pharmaceuticals's past performance and the resulting price change:
| Quarter | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.36 | -0.28 | -0.26 | -0.26 |
| EPS Actual | -0.50 | -0.34 | -0.25 | -0.29 |
| Price Change % | -5.0% | -9.0% | 3.0% | 9.0% |
Shares of Acumen Pharmaceuticals were trading at $1.19 as of March 25. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all earnings releases for Acumen Pharmaceuticals visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ABOS
